Browse topics

Clinical guides / Retina & vitreous

Diabetic retinopathy

Updated

At a glance

Retinal microvascular disease from diabetes. Classify retinopathy severity and macular oedema separately.

CAVE [1]

  • Look for neovascularisation of the disc, retina or iris, vitreous haemorrhage and traction.
  • Pregnancy can change monitoring needs.

Clinical presentation [1][2]

  • Early disease is often silent.
  • Haemorrhages, microaneurysms, venous changes and neovascularisation define the clinical pattern.
Stage each eye [1][2]
FindingActionTiming / detail
Mild NPDRMicroaneurysms onlyAssess macular oedema separately at every stage
Moderate NPDRMore than microaneurysms alone, but below severe criteriaNICE untreated disease: usually review every 6–12 months
Severe NPDR: any 4-2-1 criterion, without PDR>20 intraretinal haemorrhages in each of 4 quadrants, definite venous beading in ≥2 quadrants, or prominent IRMA in ≥1 quadrantTwo or more criteria: very severe NPDR; NICE severe/very severe untreated disease: 3–6 months
PDRDisc/elsewhere neovascularisation and/or preretinal/vitreous haemorrhage attributable to proliferative diseasePrompt retinal treatment assessment; symptoms, traction and high-risk findings increase urgency

Diagnosis & investigations [1][2]

  • Record diabetes duration/type, HbA1c trend, blood pressure, kidney disease, pregnancy and previous retinal treatment. Grade each eye from a dilated examination and suitable imaging; perform OCT for suspected oedema or unexplained acuity loss.
  • Distinguish IRMA within the retina from neovascular growth extending beyond the internal limiting membrane; angiography/OCT angiography can clarify uncertain lesions. Record macular oedema separately from the retinopathy grade. Extensive haemorrhage obscuring the fundus requires ultrasound to exclude tractional or rhegmatogenous detachment.

Differential diagnosis [1]

  • Retinal vein occlusion, hypertensive retinopathy, ocular ischaemia and other vascular retinopathies.

Treatment [1][2]

  • Coordinate glycaemia, blood pressure and renal care. Inform the diabetes team when substantial retinopathy accompanies a planned rapid HbA1c reduction so that retinal monitoring is arranged.
  • For PDR, discuss prompt PRP and anti-VEGF according to macular oedema, traction, access and likelihood of sustained follow-up. PRP offers durability; anti-VEGF needs continuing surveillance and retreatment. Loss to follow-up after injection-only management can be hazardous. Macula-threatening traction or non-clearing vitreous haemorrhage warrants vitreoretinal assessment.

Follow-up [1][2]

  • Use the staging intervals below only for the specified untreated population. Active PDR, macular treatment or postoperative disease requires a treatment-specific schedule. Shorten intervals for progression, pregnancy, rapid metabolic change or unreliable attendance. New floaters, a curtain or acute visual loss require urgent examination rather than the screening appointment.

Risk factors & context [1]

  • Duration of diabetes, glycaemic control, blood pressure, nephropathy and pregnancy influence surveillance.
  • Coordinate major metabolic treatment changes with the diabetes team.

Complications [1]

  • Macular oedema, vitreous haemorrhage, tractional detachment and neovascular glaucoma are the principal sight-threatening complications.

When to refer [1]

  • Prompt retina referral for proliferative changes, vitreous haemorrhage, traction or significant macular oedema.
References 2
  1. AAO · Diabetic Retinopathy Preferred Practice Pattern ↗2025 · Diagnosis; management; follow-up
  2. NICE · Diabetic retinopathy: management and monitoring ↗NG242 · 13 August 2024 · 1.3 Non-proliferative retinopathy; 1.4 Proliferative retinopathy; monitoring

Adapt to the patient, local pathways and authorised product information.

Evidence provenance

Evidence searched through
20 Sept 2026
Geographic applicability
Adapt to the patient, local pathways and authorised product information.
Version
fe291a631423
Guideline versions used
  • AAO · Diabetic Retinopathy Preferred Practice Pattern · 2025
  • NICE · Diabetic retinopathy: management and monitoring · NG242 · 13 August 2024
View references →